BIOA B Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
BioArctic AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 157.00 |
52 Week High | SEK 337.40 |
52 Week Low | SEK 142.90 |
Beta | -0.18 |
11 Month Change | -28.89% |
3 Month Change | -19.49% |
1 Year Change | -49.84% |
33 Year Change | 9.48% |
5 Year Change | 157.38% |
Change since IPO | 441.38% |
Recent News & Updates
Recent updates
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth
Dec 05BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate
Sep 15BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business
Aug 23Is BioArctic AB (publ) (STO:BIOA B) Trading At A 41% Discount?
Jun 03Shareholder Returns
BIOA B | SE Biotechs | SE Market | |
---|---|---|---|
7D | 3.0% | -5.9% | -6.7% |
1Y | -49.8% | 13.3% | 9.9% |
Return vs Industry: BIOA B underperformed the Swedish Biotechs industry which returned 13.3% over the past year.
Return vs Market: BIOA B underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
BIOA B volatility | |
---|---|
BIOA B Average Weekly Movement | 12.8% |
Biotechs Industry Average Movement | 8.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: BIOA B's share price has been volatile over the past 3 months.
Volatility Over Time: BIOA B's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 90 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
BIOA B fundamental statistics | |
---|---|
Market cap | SEK 13.87b |
Earnings (TTM) | -SEK 122.17m |
Revenue (TTM) | SEK 252.21m |
55.0x
P/S Ratio-113.5x
P/E RatioIs BIOA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOA B income statement (TTM) | |
---|---|
Revenue | SEK 252.21m |
Cost of Revenue | SEK 77.90m |
Gross Profit | SEK 174.31m |
Other Expenses | SEK 296.48m |
Earnings | -SEK 122.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | -1.38 |
Gross Margin | 69.11% |
Net Profit Margin | -48.44% |
Debt/Equity Ratio | 0% |
How did BIOA B perform over the long term?
See historical performance and comparison